Publicaciones Similares
Biosimilars in Latin America
The regulations for biosimilars vary
considerably from one country to
another, but in general the trend is an
increase in the regulatory standards for their health registration.
Biosimilars in Argentina
The country is currently an important producer of biopharmaceuticals, and for this reason, there are incentivization policies for the development of biosimilars…
Brazilian Health System
Guarantees universal access to health and finances the system through taxes through the Unified Health System (SUS) and a private sector.
Oppotunities for orphan drugs in Latin America
There are ample opportunities for the entry of orphan drugs into the region. The size of the Latin American orphan drug market was USD 14.17 billion in 2021 and it is estimated that it will increase by 7.38% by 2026. Based on the type of drug, the biological sector dominates the orphan drug market for Latin America
Rare Diseases current situation in Latin America and the global drug market
The size of the global market in 2021 for the treatment of rare diseases was valued at USD 119.600 million it is expected to increase at a compound annual growth rate (CAGR) of 12.8% between 2022 and 2030.
What is the inflation reduction act?
An In-Depth Examination of the Inflation Reduction Act: Unraveling its Purpose, Goals, and Impact on the Pharmaceutical Sector. Delve into the intricacies of this legislative initiative, understanding its imperative role in mitigating inflationary pressures. Navigate through the refined landscape of the pharmaceutical market, appreciating the nuanced changes implemented to fortify economic stability and foster enduring industry prosperity.